Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
Y Shimazu, J Kanda, S Kosugi, T Ito, H Kaneko… - Scientific Reports, 2023 - nature.com
Novel therapeutic drugs have dramatically improved the overall survival of patients with
multiple myeloma. We sought to identify the characteristics of patients likely to exhibit a …
multiple myeloma. We sought to identify the characteristics of patients likely to exhibit a …
Predicting the efficacy of monoclonal antibodies against multiple myeloma
Y Shimazu - 2024 - repository.kulib.kyoto-u.ac.jp
Background: Daratumumab is one of the most widely used treatments for relapsed/refractory
multiple myeloma (MM) patients. However, not all patients achieve a lasting therapeutic …
multiple myeloma (MM) patients. However, not all patients achieve a lasting therapeutic …
[PDF][PDF] Monoclonal antibody: a cell specific immunotherapy to treat cancer
MA Rahman, F Islam, M Hasan, IS Joya… - … Journal of Basic & …, 2023 - researchgate.net
Fundamentally, the therapy technique which is utilized in malignancy immunotherapy,
monoclonal antibodies (mAb), is one of them, and it is used extensively as a treatment for …
monoclonal antibodies (mAb), is one of them, and it is used extensively as a treatment for …